PMID: 8611437Apr 1, 1996Paper

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

British Journal of Cancer
F D GoebelJ S Stewart

Abstract

The utility of current chemotherapeutic regimens in the treatment of AIDS-related Kaposi's sarcoma (AIDS-KS) is often compromised by both limited efficacy and substantial toxicity. Pegylated (Stealth) liposomal doxorubicin hydrochloride (SL-DOX) has been demonstrated specifically to deliver high concentrations of doxorubicin to Kaposi's sarcoma (KS) lesions. This phase II study was performed to evaluate the efficacy and safety of SL-DOX in the treatment of moderate to severe AIDS-KS. Patients were treated biweekly with 10, 20, or 40 mg m-2 SL-DOX. Tumour response was assessed according to AIDS Clinical Trials Groups (ACTG) criteria before each cycle. Best response was determined for 238 patients and was achieved after a mean of 2.3 cycles (range 1-20). Fifteen patients (6.3%) had a complete response to SL-DOX, 177 (74.4%) had a partial response, 44 (18.5%) had stable disease and two (0.8%) had disease progression. SL-DOX was well tolerated: ten patients discontinued therapy because of adverse events, in four cases because of neutropenia. Grade 3 or 4 neutropenia occurred after 281 of 2023 cycles (13.9%) but involved 137 of 240 patients (57.1%) for whom data were available. SL-DOX has substantial activity in AIDS-KS. Best respon...Continue Reading

Citations

Jan 6, 2001·Journal of Drug Targeting·A H BrouwersF H Corstens
Jan 25, 2003·The Journal of Pharmacy and Pharmacology·Kevin J HarringtonRichard G Vile
Jul 21, 2011·Se pu = Chinese journal of chromatography·Xueqiang ZhanJingwu Kang
May 28, 2019·Journal of Cellular Biochemistry·Talíria Silva LopesPaulo Emílio Corrêa Leite
Jan 5, 2002·Expert Opinion on Investigational Drugs·K J Harrington
Nov 30, 2004·Breast Cancer Research and Treatment·Alessandro MorabitoGiampietro Gasparini
Feb 11, 1999·Australian and New Zealand Journal of Medicine·M NewellD A Cooper
Oct 27, 1998·AIDS Research and Human Retroviruses·C SmithG D Miralles
Jul 13, 2006·International Journal of Immunopathology and Pharmacology·R Di TrolioS De Placido
Aug 6, 1999·Cancer Investigation·K A Tolba, E N Deliargyris
Sep 28, 1998·Biochimica Et Biophysica Acta·K R Hande
Mar 17, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tatsuhiro IshidaHiroshi Kiwada
Sep 1, 1996·Cancer Treatment Reviews·M RansonJ Margison
Apr 8, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliUNKNOWN Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)
Jan 1, 1997·Clinical Oncology : a Journal of the Royal College of Radiologists·C P CottrillR H Phillips
May 24, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tatsuhiro IshidaHiroshi Kiwada
Dec 20, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tatsuhiro IshidaHiroshi Kiwada

❮ Previous
Next ❯

Related Concepts

Related Feeds

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.